

DAFTAR PUSTAKA

1. Alkabban FM, Ferguson T. Breast Cancer. In Treasure Island (FL); 2023.
2. Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review. *Cancers* (Basel). 2021 Aug 25;13(17):4287.
3. WHO. Absolute number of Cancer Incidence both Sexes in 2022. Global Cancer Observatory; 2022.
4. WHO. Absolute number of Cancer Mortality both sexes in 2022 .pdf. 2022.
5. International Agency Research on Cancer. Indonesia. 2020.
6. Indra. Peringatan Hari Kanker Sedunia [Internet]. Dinas Kesehatan Provinsi Sumatera Barat. 2020. Available from: <https://dinkes.sumbarprov.go.id/details/news/470#>
7. Kabir F, Tani SA, Ullah MA, Hassan AFU, Islam MJ, Ansary J, et al. Association between lymphovascular invasion (LVI) and prognostic factors in breast cancer. *J Shaheed Suhrawardy Med Coll*. 2024 May;14(2):35–8.
8. Schieman WP. Introduction to this special issue —Breast Cancer Metastasis. *J Cancer Metastasis Treat*. 2020 Feb 14;2020.
9. Redaktur W. Klasifikasi stadium tumor , node , metastasis (TNM) untuk kanker payudara. 2023;
10. Kuhn E, Gambini D, Despini L, Asnaghi D, Runza L, Ferrero S. Updates on Lymphovascular Invasion in Breast Cancer. *Biomedicines*. 2023;11(3):1–13.
11. Stevens A, Lowe J, Scott I. Core Pathology 3rd Edition. 2009.
12. Asaoka M, Patnaik SK, Zhang F, Ishikawa T, Takabe K. Lymphovascular invasion in breast cancer is associated with gene expression signatures of cell proliferation but not lymphangiogenesis or immune response. *Breast Cancer Res Treat*. 2020 Jun;181(2):309–22.
13. da Luz FAC, da Costa Marinho E, Nascimento CP, de Andrade Marques L, Delfino PFR, Antonioli RM, et al. Prognosis value of lymphovascular invasion in patients with invasive ductal breast carcinoma according to lymph node metastasis status. *Ecancermedicalscience*. 2022;16:1364.
14. Jin X, Shen C, Yang X, Yu Y, Wang J, Che X. Association of Tumor Size

With Myometrial Invasion, Lymphovascular Space Invasion, Lymph Node Metastasis, and Recurrence in Endometrial Cancer: A Meta-Analysis of 40 Studies With 53,276 Patients. Vol. 12, *Frontiers in oncology*. Switzerland; 2022. p. 881850.

15. Nishimura R, Osako T, Okumura Y, Nakano M, Ohtsuka H, Fujisue M, et al. An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer. *Oncol Lett*. 2022 Aug 1;24(2).
16. Akrami M, Meshksar A, Ghoddusi JM, Safarpour MM, Tahmasebi S, Zangouri V, et al. Prognostic Role of Lymphovascular Invasion in Patients with Early Breast Cancer. *Indian J Surg Oncol*. 2021 Dec 26;12(4):671–7.
17. Fidalgo F, Rodrigues TC, Pinilla M, Silva AG, Maciel M do S, Rosenberg C, et al. Lymphovascular invasion and histologic grade are associated with specific genomic profiles in invasive carcinomas of the breast. *Tumor Biol*. 2015 Mar 1;36(3):1835–48.
18. Kumar V, Abbas A AJ. *Robins Basic Pathology*. 10th ed. Philadelphia: Elsevier; 2017.
19. Bleiweiss IJ. *Patologi Kanker Payudara*. Jakarta : EGC. 2018;1–29.
20. Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. *Histopathology*. 2020 Aug 29;77(2):181–5.
21. Feigelson BJ. *Breast. Surg Anat Tech A Pocket Manual*, Fifth Ed. 2021;419:91–114.
22. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. *Global Cancer Statistics 2020; GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries*. *CA Cancer J Clin*. 2021 May;71(3):209–49.
23. Łukasiewicz S, Czezelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—An updated review. *Cancers (Basel)*. 2021;13(17):1–30.
24. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. *Genes Dis*. 2018 Jun;5(2):77–106.
25. Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. *Biol Res*. 2017 Oct;50(1):33.

26. Teichgraeber DC, Guirguis MS, Whitman GJ. Breast Cancer Staging: Updates in the AJCC Cancer Staging Manual, 8th Edition, and Current Challenges for Radiologists, From the AJR Special Series on Cancer Staging. *Am J Roentgenol* [Internet]. 2021 Feb 17;217(2):278–90. Available from: <https://doi.org/10.2214/AJR.20.25223>
27. Menteri Kesehatan Republik Indonesia. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara. *N Engl J Med* [Internet]. 2018;372(2):2499–508. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/7556065>
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC394507>
<http://dx.doi.org/10.1016/j.humphath.2017.05.005>
<https://doi.org/10.1007/s00401-018-1825-z>
<http://www.ncbi.nlm.nih.gov/pubmed/27157931>
28. Cserni G, Chmielik E, Cserni B, Tot T. The new TNM-based staging of breast cancer. *Virchows Arch*. 2018 May;472(5):697–703.
29. Ashariati AMI. Manajemen Kanker Payudara Komprehensif. 2019; Available from: <https://repository.unair.ac.id/96210/>
30. Masood S. Neoadjuvant chemotherapy in breast cancers. *Womens Health (Lond Engl)*. 2016 Sep;12(5):480–91.
31. Yu F, Quan F, Xu J, Zhang Y, Xie Y, Zhang J, et al. Breast cancer prognosis signature: linking risk stratification to disease subtypes. *Brief Bioinform*. 2019 Nov;20(6):2130–40.
32. Torous VF, Simpson RW, Balani JP, Baras AS, Berman MA, Birdsong GG, et al. College of American Pathologists Cancer Protocols: From Optimizing Cancer Patient Care to Facilitating Interoperable Reporting and Downstream Data Use. *JCO Clin cancer informatics*. 2021 Jan;5:47–55.
33. Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, et al. Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. *Ann Surg Oncol* [Internet]. 2017;24(1):38–51. Available from: <https://doi.org/10.1245/s10434-016-5558-8>
34. Colleoni M, Rotmensz N, Maisonneuve P, Sonzogni A, Pruneri G, Casadio C, et al. Prognostic role of the extent of peritumoral vascular invasion in operable breast cancer. *Ann Oncol Off J Eur Soc Med Oncol*. 2007 Oct;18(10):1632–40.
35. Kumar V, Abbas A AJ. *Robins Basic Pathology*. 2017.
36. Kuhn E, Gambini D, Despini L, Asnaghi D, Runza L, Ferrero S. Updates on Lymphovascular Invasion in Breast Cancer. Vol. 11, *Biomedicines*.

MDPI; 2023.

37. Sanders LM, Dardik M, Modi L, Sanders AE, Schaefer SS, Litvak A. Macroscopic lymphovascular invasion visualized on mammogram and magnetic resonance imaging: Initially misidentified as ductal carcinoma in situ but properly diagnosed by immunohistochemistry. Vol. 5, SAGE open medical case reports. England; 2017. p. 2050313X17705803.
38. Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of Breast Cancer. In: Breast Cancer. Exon Publications; 2022. p. 31–42.
39. Johnson KS, Conant EF, Soo MS. Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. Vol. 3, Journal of Breast Imaging. Oxford University Press; 2021. p. 12–24.
40. Morkavuk ŞB, Güner M, Çulcu S, Eroğlu A, Bayar S, Ünal AE. Relationship between lymphovascular invasion and molecular subtypes in invasive breast cancer. *Int J Clin Pract*. 2021 Apr 17;75(4).
41. Rakha EA, Aleskandarani M, Toss MS, Green AR, Ball G, Ellis IO, et al. Breast cancer histologic grading using digital microscopy: Concordance and outcome association. *J Clin Pathol*. 2018 Aug 1;71(8):680–6.
42. Nur F, Badruddoza SM, Asafudullah SM. Evaluation of Histopathological Diagnosis and Determination of Grades and Stages in Breast Cancer. *Asian J Med Heal*. 2022 Nov 4;204–11.
43. Santos M, Gomes C, Marcos R, Santos A, De Matos A, Lopes C, et al. Value of the Nottingham Histological Grading Parameters and Nottingham Prognostic Index in Canine Mammary Carcinoma. *Anticancer Res*. 2015 May 2;35:4219–28.
44. Kurshumliu F, Gashi-Luci L, Kadare S, Alimehmeti M, Gozalan U. Classification of patients with breast cancer according to Nottingham Prognostic Index highlights significant differences in immunohistochemical marker expression. *World J Surg Oncol*. 2014;12(1):243.
45. Gunawan Wibisana I, Briani Sobri F. CONTINUING MEDICAL EDUCATION Akreditasi PB IDI-2 SKP Biopsi Tumor Payudara. Vol. 47. 2020.
46. Elfgen C, Papassotiropoulos B, Varga Z, Moskovszky L, Nap M, Güth U, et al. Comparative analysis of confocal microscopy on fresh breast core needle biopsies and conventional histology. *Diagn Pathol* [Internet]. 2019;14(1):58. Available from: <https://doi.org/10.1186/s13000-019-0835-z>
47. Bennett IC, Saboo A. The Evolving Role of Vacuum Assisted Biopsy of

the Breast: A Progression from Fine-Needle Aspiration Biopsy. *World J Surg* [Internet]. 2019;43(4):1054–61. Available from: <https://doi.org/10.1007/s00268-018-04892-x>

48. Haddad M, Xu B, Pun C, Lu FI, Parra-Herran C, Nofech-Mozes S, et al. Breast Specimen Measurement Methodology and Its Potential Major Impact on Tumor Size. *Int J Surg Pathol*. 2021;29(1):39–45.
49. Marijanovi I, Kraljevi M, Zlatovi JJ, Buhovac T, Pavlekovi G. TUMOUR SIZE DISTRIBUTION OF INVASIVE BREAST CANCER IN A ONE-YEAR PERIOD: CASE STUDY HERZEGOVINA. Vol. 32, *Medicina Academica Mostariensia*. 2020.
50. Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. *Breast Cancer Res Treat* [Internet]. 2018 Aug 24 [cited 2025 Feb 2];170(3):647–56. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC6022519/#Fig1>
51. Mremi A, Gnanamuttupulle M, Ntundu SH, Henke O, Chilonga K, Msuya D. Invasive breast carcinoma of no special type with medullary pattern: A case report at a tertiary facility in Tanzania. *Clin Case Reports*. 2023 Aug;11(8).
52. Surabhi DM, Wilson JC, Singh M, Green L. Recognizing invasive breast carcinoma of no special type with medullary pattern. *Radiol Case Reports*. 2023 May;18(5):1788–92.
53. Christgen M, Cserni G, Floris G, Marchio C, Djerroudi L, Kreipe H, et al. Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumor. *Cancers (Basel)*. 2021 Jul;13(15):3695.
54. Cook M. Standards and datasets for reporting cancers Dataset for histopathological reporting of primary cutaneous malignant melanoma and regional lymph nodes February 2019. 2019;(February):1–49.
55. Fitzgibbons PL, Bose S, Chen YY, Connolly JL, De Baca ME, Edgerton M, et al. Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of The Breast. *Collage Am Pathol*. 2018;(January):1–32.
56. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A, et al. Breast Cancer Statistics, 2022. *CA Cancer J Clin*. 2022 Nov 3;72(6):524–41.
57. Patel JP, Jansari TR, Thorat R, Jasani J. Determination of Robinson Cytological Grading of Invasive Ductal Carcinoma of Breast. In: *Current Overview on Disease and Health Research Vol 10*. B P International (a part of SCIENCEDOMAIN International); 2023. p. 53–65.

58. Wahyudin GG, Sugiarto S, Marindawati M. Karakteristik Reseptor Estrogen, Reseptor Progesteron dan Reseptor Epidermal Manusia – 2 Uji pada Grading Histologi Karsinoma Payudara RS Pusat Pertamina Jakarta Tahun 2015 - 2020. *Muhammadiyah J Midwifery*. 2022 Dec 31;3(2):44.
59. Kiran N, Sapna F, Kiran F, Kumar D, Raja F, Shiwlani S, et al. Digital Pathology: Transforming Diagnosis in the Digital Age. *Cureus*. 2023 Sep 3;
60. Kariri YA, Aleskandarany MA, Joseph C, Kurozumi S, Mohammed OJ, Toss MS, et al. Molecular Complexity of Lymphovascular Invasion: The Role of Cell Migration in Breast Cancer as a Prototype. *Pathobiology*. 2020;87(4):218–31.
61. Valencia-Cedillo R. Sampling and Evaluation of the Breast Surgical Specimens. In: *Practical Atlas of Breast Pathology*. Springer International Publishing; 2018. p. 475–89.
62. Li X, Luo K, Zhang N, Chen W, Li B, Lu Z, et al. Prediction of Lymphovascular invasion status in breast cancer based on magnetic resonance imaging radiomics features. *Magn Reson Imaging*. 2024 Jun;109:91–5.
63. Koleoso OA, Toumbacaris N, Zhang Z, Braunstein LZ, El-Tamer M, Moo TA, et al. The Presence of Extensive Lymphovascular Invasion (LVI) is Associated with Higher Risk of Recurrence in Curatively Treated Breast Cancer Patients. *Int J Radiat Oncol*. 2023 Oct;117(2):S135–6.
64. Coşkun Bilge A, Yaltrık Bilgin E, Bulut ZM, Esen Bostancı I, Bilgin E. Preoperative Dynamic Contrast-Enhanced and Diffusion-Weighted Breast Magnetic Resonance Imaging Findings for Prediction of Lymphovascular Invasion of the Lesions in Node-Negative Invasive Breast Cancer. *Can Assoc Radiol J*. 2024 May 14;75(2):386–96.
65. Zhang C, Zhou P, Li R, Li Z, Ouyang A. Prediction of lymphovascular invasion in invasive breast cancer based on clinical-MRI radiomics features. *BMC Med Imaging*. 2024 Oct 16;24(1):277.
66. Zhao Y, Yang N, Wang X, Huang Y, Zhou X, Zhang D. Potential roles of lymphovascular space invasion based on tumor characteristics provide important prognostic information in T1 tumor with ER and HER2 positive breast cancer. *Clin Transl Oncol*. 2020 Dec 23;22(12):2275–85.
67. Sasidharan S, Chirukandath R, Krishnan S, Nazrin R, Meera M, Veeshma P. Lymphovascular Invasion and Ductal In-situ Components in Operable Infiltrating Duct Carcinoma of Breast A Single Centre Experience. *J Clin DIAGNOSTIC Res*. 2022;
68. Laser J, Cangiarella J, Singh B, Melamed J, Chiriboga L, Yee H, et al.

Invasive lobular carcinoma of the breast: role of endothelial lymphatic marker D2-40. *Ann Clin Lab Sci.* 2008;38(2):99–104.

69. Andika M. Faktor Keterlambatan Diagnosis Kanker Payudara Pada Penderita Kanker Payudara Di Poli Bedah RSUP Dr. M. Djamil Padang. *J Penelit dan Kaji Ilm.* 2023;1–9.
70. Amelia D, Srywahyuni A, Ilmu Kesehatan F, Mohammad Natsir Bukittingi U. Gambaran Faktor Resiko Kanker Payudara Pada Penderita Kanker Payudara Di Bukittinggi. 2023.

